Biomedical subjects

L M Ena

Publications and source records attributed to L M Ena.

At least 19 recordsLinked to original sources

PubMed1992

[Effect of antihypertensive therapy with captopril on gluco- and mineralocorticoid receptors of peripheral blood lymphocytes in hypertensive patients of various age].

Binding of 3H-dexamethasone and 3H-aldosterone by peripheral lymphocyte receptors was investigated in healthy persons and hypertensive patients before and after 2-week captopril treatment. The number of glucocorticoid and mineralocorticoid binding sites was increased in hypertensives vs normotensives. The treatment with the ACE inhibitor captopril led to activation of hormone-receptor interactions. There was a more marked rise of the number of receptors in middle-aged (44-55 years) hypertensives vs elderly (61-80 years) subjects after captopril treatment.

Adult↗

PubMed1990

[The effect of sermion on the main hemodynamic indices in patients with the initial manifestations of cerebral atherosclerosis].

It has been found that the drug sermion (nicergoline)--a synthetic ergot alkaloid with alpha-adrenoblocking action--produces a pronounced vasoactive (spasmolytic) effect in the elderly patients suffering of initial atherosclerotic encephalopathy. A course of sermion treatment improves, via its effect on the brain and lower extremity vessels, the flow in most involved vascular regions. High concentrations of the drug after intravenous administration of 4 mg of sermion (nicergoline) result in a rise of the sympathetic vascular tone, high adrenoblocking action.

Administration, Oral↗

PubMed1990

[Age-related characteristics of the prostaglandin system in healthy subjects and in patients with arterial hypertension: hypertonic disease and systolic (atherosclerotic) hypertension].

A group of 89 apparently healthy subjects and 175 patients with essential hypertension (EH) and systolic (atherosclerotic) hypertension aged 25 to 74 years were surveyed. The healthy subjects were found to have changes in prostaglandin (PG) synthesis and metabolism: a reduction in blood plasma concentration of PGE2 and its urinary excretion, a rise in plasma PGF2 level, and, generally, increase in the pressor and decrease in depressor potentials of the PG system. In the EH patients, changes in the PG synthesis and metabolism were unidirectional and had quantitative variations. The differences in the PG levels of healthy and EH-afflicted individuals were found to become less marked with age. The patients with systolic hypertension exhibited higher plasma prostacyclin concentrations as compared to the age-matching control, which is evidence of a lower pressor potential of the PG system than that of the EH patients. The nature and magnitude of changes in the PG system play a certain role in blood pressure formation and in development of the hemodynamic variant of arterial hypertension.

Adult↗

PubMed1989

[Essentiale in the treatment of hypertension in patients in the older age groups].

The authors studied the effect of essentiale on the clinical course, state of central hemodynamics and content of prostaglandins in the blood and urine of patients with hypertensive disease. Age of the patients: middle--from 45 to 59 years and elderly--from 60 to 74 years. It is suggested that the hypotensive effect of essentiale is caused by a reduction of the total peripheral resistance while its humoral basis is an increase of the depressor potential of plasma and renal prostaglandins. Age-related differences in the response to essentiale treatment consist mostly in the effect on the clinical symptoms, arterial pressure, prostaglandins in the blood and urine differing in the elderly as compared with medium-aged patients.

Aged↗

PubMed1985